Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DOXAZOSIN Mesylate Tablet (GREENSTONE LLC) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Doxazosin safely and effectively. See full prescribing information for Doxazosin.

Doxazosin tablets, for oral use
Initial U.S. Approval: 1990

INDICATIONS AND USAGE

Doxazosin is an alpha1 adrenergic antagonist indicated for: (1)

  • Signs and symptoms of Benign Prostatic Hyperplasia (BPH)
  • Treatment of Hypertension

DOSAGE AND ADMINISTRATION

  • For the treatment of BPH: Initiate therapy at 1 mg once daily. Dose maybe titrated at 1 to 2-week intervals, up to 8 mg once daily. (2.2)
  • For the treatment hypertension: Initiate therapy at 1 mg once daily. Dose may be titrated as needed, up to 16 mg once daily. (2.3)

DOSAGE FORMS AND STRENGTHS

  • Tablets: 1 mg, 2 mg, 4 mg, 8 mg.

CONTRAINDICATIONS

  • Hypersensitivity to doxazosin, other quinazolines, or any other ingredient in Doxazosin. (4)

WARNINGS AND PRECAUTIONS

  • Postural hypotension with or without syncope may occur. (5.1)
  • Risk of Intraoperative Floppy Iris Syndrome during cataract surgery. (5.2)
  • Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards. (5.3)

ADVERSE REACTIONS

The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness. (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Greenstone LLC Professional Information Services at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (7.1)
  • Concomitant administration of Doxazosin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. (7.2)

USE IN SPECIFIC POPULATIONS

  • Hepatic Impairment: Monitor for hypotension. (8.6, 12.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 6/2021

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event